A review of mammalian carcinogenicity study design and potential effects of alternate test procedures on the safety evaluation of food ingredients

Regulatory Toxicology and Pharmacology

Volumn 59, Issue 1, 2011, Pages S1-S34

  Hayes, A W ^b,f   Dayan, A D ^d   Hall, W C ^a   Kodell, R L ^c   Williams, G M ^e   Waddell, W D ^g   Slesinski, R S ^f   Kruger, C L ^f  

^a Hall Consulting Services ^*  (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^d UNIVERSITY OF LONDON   (United Kingdom)

^e NEW YORK MEDICAL COLLEGE   (United States)

^f Spherix Consulting   (United States)

^g UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

Carcinogenicity; Food ingredients; Study design

Indexed keywords

FOOD ADDITIVE;

ANIMAL HOUSING; ANIMAL WELFARE; ARTICLE; BIOASSAY; BREEDING; CARCINOGENICITY; CLINICAL CHEMISTRY; CLINICAL EXAMINATION; CLINICAL PROTOCOL; CROWDING; DIETARY INTAKE; DRUG ADSORPTION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG PURITY; DRUG STABILITY; EXPERIMENTAL ANIMAL; FOOD HANDLING; GENETIC VARIABILITY; GOOD LABORATORY PRACTICE; HEALTH HAZARD; HISTOPATHOLOGY; LABORATORY TEST; LIFESPAN; METHODOLOGY; NONHUMAN; PRIORITY JOURNAL; SCREENING TEST; STUDY DESIGN; URINALYSIS; ANIMAL; CARCINOGEN TESTING; FOOD SAFETY; HUMAN; PRODUCT SAFETY; RISK ASSESSMENT;

ANIMALIA; MAMMALIA; RATTUS; RODENTIA;

ANIMALS; CARCINOGENICITY TESTS; CONSUMER PRODUCT SAFETY; FOOD SAFETY; HUMANS; RISK ASSESSMENT;

EID: 84873054762     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2010.10.002     Document Type: Article

References (209)

1. Abdo K.M., Kari F.W. The sensitivity of the NTP bioassay for carcinogen hazard evaluation can be modulated by dietary restriction. Exp. Toxicol. Pathol. 1996, 48:129-137.
2. ACVP (American College of Veterinary Pathologists), 2009. Certifying examinations and qualifications. Available from: (accessed October, 2009). http://www.acvp.org/exam/.
3. Alexandrov, V., Aiello, C., Rossi, L., 1990. Modifying factors in prenatal carcinogenesis (review). In Vivo 5, 327-335.
4. Allaben W.T., Turturro A., Leakey J.E.A., Seng J.E., Hart R.W. FDA points-to-consider documents: the need for dietary control for the reduction of experimental variability within animal assays and the use of dietary restriction to achieve dietary control. Toxicol. Pathol. 1996, 24:776-781.
5. Bailer A.J., Portier C.J. Effects of treatment-induced mortality and tumor-induced mortality on tests for carcinogenicity in small samples. Biometrics 1988, 44:417-431.
6. Balcombe J.P., Barnard N.D., Sandusky C. Laboratory routines cause animal stress. Contemp. Topics Lab. Animal Sci. 2004, 43:42-51.
7. Baldrick P. Carcinogenicity evaluation: comparison of tumor data from dual control groups in the Sprague-Dawley Rat. Toxicol. Pathol. 2005, 33:283-291.
8. Baldrick P., Reeve L. Carcinogenicity evaluation: comparison of tumor data from dual control groups in the CD-1 mouse. Toxicol. Pathol. 2007, 35:562-569.
9. Barton H.A., Pastoor T.P., Baetcke K., Chambers J.E., Diliberto J., Doerrer N., Driver J.H., Hastings C.E., Iyengar S., Krieger R., Stahl B., Timchalk C. The acquisition and application of absorption, distribution, metabolism, and excretion (ADME) data in agricultural chemical safety assessments. Crit. Rev. Toxicol. 2006, 36:9-35.
10. Belpoggi F., Soffritti M., Tibaldi E., Falcioni L., Bua L., Trabucco F. Results of long-term carcinogenicity bioassays on Coca-Cola administered to Sprague-Dawley rats. Ann. NY Acad. Sci. 2006, 1076:736-752.
11. Belpoggi F., Soffritti M., Padovani M., Degli Esposti D., Lauriola M., Minardi F. Results of long-term carcinogenicity bioassay on Sprague-Dawley rats exposed to aspartame administered in feed. Ann. NY Acad. Sci. 2006, 1076:559-577.
12. Black H.E. Peer review in toxicologic pathology: some recommendations. Toxicol. Pathol. 1991, 19:290-292.
13. Bomhard E. Frequency of spontaneous tumors in Wistar rats in 30-month studies. Exp. Toxicol. Pathol. 1992, 44:381-392.
14. Bomhard E. Frequency of spontaneous tumours in NMRI mice in 21-month studies. Exp. Toxicol. Pathol. 1993, 45:269-289.
15. Bomhard E., Mohr U. Spontaneous tumors in NMRI mice from carcinogenicity studies. Exp. Pathol. 1989, 36:129-145.
16. Bomhard E., Rinke M. Frequency of spontaneous tumours in Wistar rats in 2-year studies. Exp. Toxicol. Pathol. 1994, 46:17-29.
17. Bomhard E., Karbe E., Loeser E. Spontaneous tumors of 2000 Wistar TNO/W.70 rats in two-year carcinogenicity studies. J. Environ. Pathol. Toxicol. Oncol. 1986, 7:35-52.
18. Brix A.E., Nyska A., Haseman J.K., Sells D.M., Jokinen M.P., Walker N.J. Incidences of selected lesions in control female Harlan Sprague-Dawley rats from two-year studies performed by the National Toxicology Program. Toxicol. Pathol. 2005, 33:477-483.
19. Buchanan J.R., Burka L.T., Melnick R.L. Purpose and guidelines for toxicokinetic studies within the National Toxicology Program. Environ. Health Perspect. 1997, 105:468-471.
20. Bucher J.R. The national toxicology program rodent bioassay, designs, interpretations, and scientific contributions. Ann. NY Acad. Sci. 2002, 982:198-207.
21. Cameron T.P., Hickman R.L., Kornreich M.R., Tarone R.E. History, survival and growth patterns of B6C3F1 mice and F344 rats in the National Cancer Institute carcinogenesis testing program. Fund. Appl. Toxicol. 1985, 5:526-538.
22. Chandra M., Frith C.F. Spontaneous neoplasms in aged control Fischer 344 rats. Cancer Lett. 1992, 62:49-56.
23. Chandra M., Riley M.G.I., Johnson D.E. Spontaneous neoplasms in aged Sprague-Dawley rats. Arch. Toxicol. 1992, 66:496-502.
24. Chapin R.E., DK Gulati, Barnes L.H., Teague J.L. The effects of feed restriction on reproductive function in Sprague-Dawley rats. Fund. Appl. Toxicol. 1993, 20:23-29.
25. Chow, S.C., Liu, J.P., 1998. Design and Analysis of Animal Studies in Pharmaceutical Development. Marcel Dekker, NY, 406 pp.
26. Christian M.S., Hoberman A.M., Johnson M.D., Ray Brown W., Bucci T.J. Effect of dietary optimization on growth, survival, tumor incidences and clinical pathology parameters in CD Sprague-Dawley and Fischer-344 rats: a 104-week study. Drug Chem. Toxicol. 1998, 21:97-117.
27. Clark D.E., Elissalde M.H., Doyle J.J., Mollenhauer H.H. Interaction of environmental stress and hexachlorobenzene in the laboratory rat. J. Toxicol. Environ. Health 1981, 8:297-306.
28. Cogliano V.J., Baan R.A., Straif K., Grosse Y., Secretan M.B., El Ghissassi F., Kleihues P. The science and practice of carcinogen identification and evaluation. Environ. Health Perspect. 2004, 112:1269-1274. Available from: .
29. Cohen S., Robinson D., MacDonald J. Alternative models for carcinogen testing. Toxicol. Sci. 2001, 64:14-19. Available from: .
30. Combes R., Schechtman L., Stokes W.S., Blakey D. The International Symposium on Regulatory Testing and Animal Welfare: Recommedations on best scientific practices for subchronic/chronic toxicity and carcinogenicity testing. ILAR J. 2002, 43(Suppl.):S112-S117. Available from: .
31. Contrera J.F., Jacobs A.C., Prasanna H.R., Mehta M., Schmidt W.J., DeGeorge J. A systemic exposure-based-alternative to the maximum tolerated dose for carcinogenicity studies of human therapeutics. J Amer. College Toxicol. 1995, 14:1-10.
32. Contrera J.F., Jacobs A.C., DeGeorge J.J. Carcinogenicity testing and the evaluation of regulatory requirements for pharmaceuticals. Regul. Toxicol. Pharmacol. 1997, 25:130-145.
33. Council of Europe, 2006. Appendix A of the European Convention for the protection of vertebrate animals used for experimental and other scientific purposes (ETS NO. 123): Guidelines for Accomodation and Care of Animals (Article 5 of the Convention) Approved by the Multilateral Consultation. Strassburg. Available from: (accessed December 2009). http://www.coe.int.
34. Counts J.L., Goodman J.I. Principles underlying dose selection for, and extrapolation from, the carcinogen bioassay: dose influences mechanism. Reg. Toxicol. Pharmacol. 1995, 21:418-421.
35. Crissman J.W., Goodman D.G., Hildebrandt P.K., Maronpot R.R., Prater D.A., Riley J.H., Seaman W.J., Thake D.C. Society of Toxicologic Pathologists best practices guideline: toxicologic histopathology. Toxicol. Pathol. 2004, 32:126-131.
36. CRL (Charles River Laboratories, Inc.), 2009. CRL® IGS (SD) rat model. Available from: (accessed October, 2009). http://www.criver.com/en-US/ProdServ/ByType/ResModOver/ResMod/Pages/CDRat.aspx.
37. Davies T.S., Lynch B.S., Monro A.M., Munro I.C., Nestmann E.R. Rodent carcinogenicity tests need be no longer than 18 months: an analysis based on 210 chemicals in the IARC monographs. Food Chem. Toxicol. 2000, 38:219-235.
38. Decreto Legislativo 116, 1992. Attuazione della direttiva. 86/609/CEE in materia di protezione degli animali utilizzati a fini sperimentali o ad altri fini scientifici [in Italian]. Supplemento ordinario alla Gazzetta Ufficiale 40, 5-25. Cited in: Soffritti et al. (2006).
39. Deschl U., Kittel B., Rittinghausen S., Morawietz G., Kohler M., Mohr U., Keenan C. The value of historical control data - scientific advantages for pathologists, industry and agencies. Toxicol. Pathol. 2002, 30:80-87.
40. EC (European Commission), 1986. Council Directive 86/609/EEC of 24 November 1986 on the approximation of laws, regulations and administrative provisions of the Member States regarding the protection of animals used for experimental and other scientific purposes. Available from: (accessed October, 2009). http://eur-lex.europa.eu/smartapi/cgi/.
41. EC (European Commission), 2009. Implementation of GLP directives in the European states: Directives 2004/9/EC and 2004/10/EC. Available from: (accessed November, 2009). http://ec.europa.eu/enterprise/.
42. EFSA (European Food Safety Authority), 2006. Opinion of the Scientific Panel on Food Additives, Flavourings, Processing Aids and Materials in Vontact with Food (AFC) on a request from the Commission related to a new long-term carcinogenicity study on aspartame. Question number EFSA-Q-2005-122. Adopted May 3, 2006. The EFSA J. 356, 1-44.
43. EFSA, 2009. Updated Scientific Opinion of the Panel on Food Additives and Nutrient Sources added to Food on a request from the European Commission related to the 2nd ERF carcinogenicity study on aspartame taking into consideration study data submitted by the Ramazzini Foundation in February 2009. EFSA-Q-2009-00474. Adopted March 19, 2009. The EFSA J. 1015, 1-18.
44. Elmore S.A., Peddada S.D. Points to consider on the statistical analysis of rodent cancer bioassay data when incorporating historical control data. Toxicol. Pathol. 2009, 37:672-676.
45. EMEA (European Medicines Evaluation Agency), 2005. Guideline on the evaluation of control samples in nonclinical safety studies: checking for contamination with the test substance. Committee for Medicinal Products for Human Use. CPMP/SWP/1094/04. Available from: (accessed December 2009). http://www.emea.europa.eu/.
46. EPA, 1983. Environmental Protection Agency Good laboratory practice standards. (Source: 48 FR 52922, Nov.29, 1983). 40 CFR Part 160.1-160.195. 7/1/2007 Ed. Available from: (accessed October, 2009). http://www.access.gpo.gov/.
47. EPA, 1984. Environmental Protection Agency - Fungicides, Insecticides and Rodenticides Act. 48 Federal Register 53946. Effective May 2, 1984. Available from: (accessed October, 2009). http://www.epa.gov/oecaerth/monitoring/programs/fifra/glp.html.
48. EPA, 1998. Environmental Protection Agency, Office of Prevention, Pesticide and Toxic Substances. Health Effect Test Guidelines OPPTS 870-4200: Carcinogenicity. EPA 712-C-98-211. Available from: (accessed October, 2009). http://www.epa.gov/.
49. EPA, 2005. Guidelines for Carcinogen Risk Assessment (Cancer Guidelines). Federal Register Notice. Available from: http://cfpub.epa.gov/.
50. Ertz K., Preu M. International GLP: a critical reflection on the harmonized global standard from a test facility viewpoint. Annali del Instituto Superiore di Sanita 2008, 44:390-394.
51. ESTP (European Society of Toxicologic Pathology), 2005. Regarding Society of Toxicology Pathology (STP) " Revision of standardized nomenclature for lesions in the rat and mouse" Unpublished Letter from W. Kauffmann, President of ESTP to Nancy Evards, President STP, September 19, 2005.
52. ESTP (European Society of Toxicologic Pathology), 2007. Accreditation as " IFSTP/IATP Accredited Toxicologic Pathologist" October 2007 Draft SOP. Available from: (accessed October, 2009). http://www.eurotoxpath.org/.
53. Ettlin R.A., Bolon B., Pyrah I., Konishi Y., Black H.E. Global recognition of toxicologic pathologists: where we are now and where we need to go. J. Toxicol. Pathol. 2007, 20:267-272.
54. Fairweather W.R., Bhattacharyya A., Ceuppens P.P., Heimann G., Hothorn L.A., Kodell R.L., Lin K.K., Mager H., Middleton B.J., Slob W., Soper K.A., Stallard N., Ventre J., Wright J. Biostatistical methods in carcinogenicity studies. Drug Inform. J. 1998, 32:401-421.
55. Faustman, E.L., Omenn, G.S., 2008. In: Klaassen, C.D. (Ed.), Risk Assessment, in Casarett & Doull;s Toxicology, seventh ed., p. 112.
56. FDA, 1978. Good laboratory practice for non-clinical laboratory studies. (Source: 43 FR 60013, December 22, 1978; as amended at 52 FR 33779, September 4, 1987). 21 CFR Parts 58.1 - 58.219. 4/1/2007 Ed. Available from: (accessed October, 2009). http://www.access.gpo.gov/.
57. FDA, 2000a. Toxicological principles for the safety assessment of food ingredients: FDA Redbook 2000: Section IV.B.1. General guidelines for designing and conducting toxicity studies. November 2003, 18 pp. Available from: (accessed October, 2009). http://www.fda.gov/Food/GuidanceComplianceRegulatoryInformation/GuidanceDocuments/FoodIngredientsandPackaging/Redbook/ucm078315.htm.
58. FDA, 2000b. Toxicological principles for the safety assessment of food ingredients: FDA Redbook 2000: Section IV.C.6. Carcinogenicity studies with rodents. January 2006, 21 p. Available from: (accessed October, 2009). http://www.fda.gov/Food/GuidanceComplianceRegulatoryInformation/GuidanceDocuments/FoodIngredientsandPackaging/Redbook/ucm078388.htm.
59. FDA, 2000c. Toxicological principles for the safety assessment of food ingredients: FDA Redbook 2000: Section IV.C.8. In utero exposure phase for addition to carcinogenicity studies or chronic toxicity studies with rodents. July 2007, 26 pp. Available from: (accessed October, 2009). http://www.fda.gov/Food/GuidanceComplianceRegulatoryInformation/GuidanceDocuments/FoodIngredientsandPackaging/Redbook/ucm078394.htm.
60. FDA, 2000d. Toxicological principles for the safety assessment of food ingredients: FDA Redbook 2000: Section IV.B.3. Pathology considerations in toxicity studies. July 2000, 8 pp. Available from: (accessed October, 2009). http://www.fda.gov/Food/GuidanceComplianceRegulatoryInformation/GuidanceDocuments/FoodIngredientsandPackaging/Redbook/ucm078318.htm.
61. FDA, 2000e. Toxicological principles for the safety assessment of food ingredients: FDA Redbook 2000: Section IV.B.4. Statistical considerations in toxicity studies. July 2000, 9 pp. Available from: (accessed October, 2009). http://www.fda.gov/Food/GuidanceComplianceRegulatoryInformation/GuidanceDocuments/FoodIngredientsandPackaging/Redbook/ucm078320.htm.
62. FDA, 2000f. Toxicological principles for the safety assessment of food ingredients: FDA Redbook 2000: Section IV.B.2. Guidelines on reporting the results of toxicity studies. November 2003, 8 pp. Available from: (accessed October, 2009). http://www.fda.gov/Food/GuidanceComplianceRegulatoryInformation/GuidanceDocuments/FoodIngredientsandPackaging/Redbook/ucm078409.htm.
63. FDA, 2001. Center for Drug and Evaluation and Research. Guidance for industry: Statistical aspects of the design, analysis and interpretation of chronic rodent carcinogenicity studies of pharmaceuticals. Draft guidance, KKK Lin, FDA. Available from: (accessed October, 2009). http://www.fda.gov/.
64. FDA, 2007. Center for Food Safety and Applied Nutrition. FDA Statement on European Aspartame Study. April 20, 2007. Available from: (accessed November, 2009). http://www.cfsan.fda.gov/.
65. FDA, 2008a. Guidance for Industry. S1C(R2) Dose selection for carcinogenicity studies. Center for Drug Evaluation and Research (CDER); Center for Biologics Evaluation and Research (CBER). September 2008: ICH Revision 1. Fed. Reg. 60, 11278-11281; Addendum published in the Fed. Reg. 62, 64260.
66. FDA, 2008b. CFSAN/Office of Food Safety: Total Diet Study, Study Design. Available from: (accessed November, 2009). http://www.fda.gov/Food/FoodSafety/FoodContaminantsAdulteration/TotalDietStudy/ucm184232.htm.
67. Foran J.A. Principles for the selection of doses in chronic rodent bioassays. ILSI Risk Science Working Group on Dose Selection. Environ. Health Perspect. 1997, 105:18-20.
68. French, J.E., Spalding, J.W., Dunnick, J.K., Tice, R.R., Furedi-Machacek, M., Tennant, R.W., 1999. The use of transgenic animals in cancer testing. Inhal. Toxicol. 11, 541-544.
69. Gad, S.C., McCord, M.G., 2008. Carcinogenicity. In: Safety Evaluation in the Development of Medical Devices and Combination Products, third ed. Informa Healthcare, USA, NY, pp. 197-202.
70. Gad S.C., Weil C.S. Statistics and Experimental Design for Toxicologists 1986, The Telford Press, NJ, 380 pp.
71. Gart, J.J., Krewski, D., Lee, P.N., Tarone, R.E., Wahrendorf, J., 1986. Statistical Methods in Cancer Research, vol. III, The Design and Analysis of Long-term Animal Experiments. International Agency for Research on Cancer, Lyon, 219 pp.
72. Gaylor D.W., Swirsky Gold L. Regulatory cancer risk assessment based on a quick estimate of a benchmark dose derived from the maximum tolerated dose. Reg. Tox. Pharmacol. 1998, 2S:222-225.
73. Gaylor D.W., Chen J.J., Kodel R.L. Experimental design of bioassays for screening and low dose extrapolation. Risk Anal. 1985, 5:9-16. Cited in: Rhomberg et al. (2007).
74. Gehring P.J., Blau G.E. Mechanisms of carcinogenesis: dose response. J Environ. Path. Toxicol. 1977, 1:163-179.
75. Gehring P.J., Watanabe P.G., Park C.N. Resolution of dose-response toxicity data for chemicals requiring metabolic activation: example vinyl chloride. Toxicol. Appl. Pharmacol. 1978, 44:581-591. Cited in Haseman (1985) referenced herein.
76. Goodman J.I. A perspective on current and future uses of alternative models for carcinogenicity testing. Toxicol. Pathol. 2001, 29(Suppl.):173-176.
77. Goodman, D.G., Boorman, G.A., Strandberg, J.D., 1994. Selection and use of the B6C3HF1 mice and F344 rats in long-term assays for carcinogenicity. In: Handbook of Carcinogen Testing, second ed., 904 pp. William Andrew Publ., NY, pp. 347-390.
78. Greim H., Gelbke H.-P., Reuter U., Thielmann H.W., Edler L. Evaluation of historical control data in carcinogenicity studies. Hum. Exper.Toxicol. 2003, 22:541-549.
79. Hailey, J.R., 2004. Pathology Working Group Chairperson's Report. Lifetime study in rats conducted by the Ramazzini Foundation. Prepared by James R. Hailey, Pathology Working Group Chair. National Institute of Environmental Health Sciences, Research Triangle Park, USA. Submitted to: Dr. Fiorella Belpoggi, Ramazzini Foundation, Bologna, Italy. November 30, 2004: Cited In Report from: Committee on Carcinogenicty of Chemicals in Food, Consumer Products and the Environment: Statement on a Carcinogenicity Study of Aspartame by the European Ramazzini Foundation; Statement COC/06/S2 - December 2006. Available from: (accessed November 2009). http://www.iacoc.org.uk/.
80. Hamm T.E. Design of a long-term animal bioassay for carcinogenicity. Handbook of Carcinogen Testing 1994, 270-285. Noyes Publications, NJ, 904 pp. second ed. H.A. Milman, E.K. Weisburger (Eds.).
81. Hart R.W., Kennan K., Turturro A., Abdo K.M., Leakey J., Lyn-Cook B. Caloric restriction and toxicity. Fund. Appl. Toxicol. 1995, 25:184-195.
82. Haseman J.K. Issues in carcinogenicity testing: dose selection. Fund. Appl. Toxicol. 1985, 5:66-78.
83. Haseman J.K. Value of historical controls in the interpretation of rodent tumor data. Drug Info. 1992, 26:191-200.
84. Haseman J.K., Hoel D.G. Statistical design of toxicity assays: role of genetic structure of test animal population. J. Environ. Pathol. Toxicol. 1979, 2:1313-1327.
85. Haseman J.K., Lockhart A. The relationship between use of the maximum tolerated dose and study sensitivity for detecting rodent carcinogenicity. Fund. Appl. Toxicol. 1994, 22:382-391.
86. Haseman J.K., Huff J., Boorman G.A. Use of historical control data in carcinogenicity studies in rodents. Toxicol. Pathol. 1984, 12:126-135.
87. Haseman J.K., Winbush J.S., O'Donnell M.W. Use of dual control groups to estimate false positive rates in laboratory animal carcinogenicity studies. Fund. Appl. Toxicol. 1986, 7:573-584.
88. Haseman J.K., Huff J.E., Rao G.N., Eustis S.L. Sources of variability in rodent carcinogenicity studies. Fund. Appl. Toxicol. 1989, 12:793-804.
89. Haseman J.K., Young E., Eustis S.L., Hailey J.R. Body weight-tumor incidence correlations in long-term rodent carcinogenicity studies. Toxicol. Pathol. 1997, 25:256-263.
90. Haseman J.K., Hailey J.R., Morris R.W. Spontaneous neoplasm incidences in Fischer 344 rats and B6C3F1 mice in two-year carcinogenicity studies: National Toxicology Program update. Toxicol. Pathol. 1998, 26:428-441.
91. Haseman J., Melnick R., Tomatis L., Huff J. Carcinogenesis bioassays: study duration and biological relevance. Food Chem. Toxicol. 2001, 39:739-744.
92. Haseman J.K., Ney E., Nyska A., Rao G.N. Effect of diet and animal care/housing protocols on body weight, survival, tumor incidences, and nephropathy severity of F344 rats in chronic studies. Toxicol. Pathol. 2003, 31:674-681.
93. Hattis D., Goble R., Chu M. Age-related differences in susceptibility to carcinogenesis. II. Approaches for applicatiuon and uncertainty analyses for individual genetically acting carcinogens. Environ. Health Perspect. 2005, 113:509-516.
94. Hollander C.F., Solleveld H.A., Zurcher C., Nooteboom A.L., Van Zwieten M.J. Biological and clinical consequences of longitudinal studies in rodents: their possibilities and limitations. An overview. Mech. Aging Develop. 1984, 28:249-260.
95. Huff J. Long-term chemical carcinogenesis bioassays predict human cancer hazards. Ann. NY Acad. Sci. 1999, 895:56-79.
96. Huff J. Chemicals studied and evaluated in long-term carcinogenesis bioassays by both the Ramazzini foundation and the National Toxicology program. In tribute to Cesare Maltoni and David Rall. Ann. NY Acad. Sci. 2002, 982:208-230.
97. Huff J., Jacobson M.F., Davis D.L. The limits of two-year bioassay exposure regimens for identifying chemical carcinogens. Environ. Health Perspect. 2008, 116:1439-1442.
98. Hurst J.L., Barnard C.J., Tolladay U., Nevision C.M., West C.D. Housing and welfare in laboratory rats: effects of cage stocking density and behavioural predictors of welfare. Animal Behav. 1999, 58:563-586.
99. IARC (International Agency for Research on Cancer), 1980. Long-term and short-term screening assays for carcinogens: a critical appraisal. IARC Monographs Suppl. 2, Lyon.
100. IARC, 1999. The use of short- and medium-term tests for carcinogens and data on genetic effects in carcinogenic hazard evaluation. In: McGregor, D.B., Rice, J.M., Venit, S. (Ed.), IARC Scientific Publications No. 146. Lyon, France. Available from: http://monographs.iarc.fr/ENG/Publications/index1.php.
101. IARC, 2000: IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Lyon, France, World Health Organization.
102. IARC, 2006. IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans: Preamble to the IARC monographs (amended January 2006). Lyon, France. Available from: (accessed November, 2009). http://monographs.iarc.fr/ENG/Classification/index.php.
103. Iatropoulos, M.J., 1988. Society of toxicologic pathologists position paper: " Blinded" microscopic examination of tissues from toxicologic or oncogenic studies. In: Grice, H.C., Ciminera, J.L. (Eds.), Carcinogenicity. The Design, Analysis and Interpretation of Long-term Animal Studies. Proceedings of the Interdisciplinary Discussion Group on Carcinogenicity Studies held in Chapel Hill, NC, June 1986 ILSI Monographs. Springer-Verlag, NY.
104. ICH (International Conference for Harmonization). 1997. Testing for carcinogenicity of pharmaceuticals. Guideline S1B. US Fed. Reg. 63: 8983; EU: CPMP/ICH/299/95. Available from: (accessed October, 2009). http://www.ich.org/.
105. ICH, 2008. Dose selection for carcinogenicity studies of pharmaceuticals. Guideline S1C(R2). US Fed. Reg. 60, 11278-11281; EU CHMP/ICH/383/1995. Available from: (accessed November, 2009). http://www.ich.org/.
106. Imai D., Yoshimura S., Yamaguchi K., Matsui E., Isaka H., Hashimoto K., Boorman G.A. Effects of dietary restriction on age-associated pathologic changes in F-344 rats. J. Toxicol. Pathol. 1990, 3:209-221.
107. Jameson C.S., Goehl T.J. Chemistry requirements for toxicological and carcinogenicity evaluation of chemicals. Handbook of Carcinogen Testing 1994, 286-297. Noyes Publications, NJ, 904 pp. second ed. H.A. Milman, E.K. Weisburger (Eds.).
108. Jena G.B., Kaul C.L., Ramarao P. Regulatory requirements and ICH guidelines on carcinogenicity testing of pharmaceuticals: a review on current status. Indian J. Pharmacol. 2005, 37:209-222.
109. Johnson M.D. The rat: toxicology. Animal Models in Toxicology 2006, 150-192. Taylor & Francis Group, LLC Publ., NY, NY, 933 pp. second ed. S.C. Gad (Ed.).
110. Keenan K.P. The uncontrolled variable in risk assessment: ad libitum overfed rodents - fat, facts and fiction. Toxicol. Pathol. 1996, 24:376-383.
111. Keenan K.P., Smith P.F., Hertzog P., Soper K., Ballam G.C., Clark R.L. The effects of overfeeding and dietary restriction on Sprague Dawley rat survival and early pathology biomarker of aging. Toxicol. Pathol. 1994, 22:300-315.
112. Keenan K.P., Laroque P., Ballam G.C., Soper K.A., Dixit R., Mattson B.A., Adams S.P., Coleman J.B. The effects of diet, ad libitum overfeeding, and moderate dietary restriction on the rodent bioassay: the uncontrolled variable in safety assessment. Toxicol. Pathol. 1996, 24:757-768.
113. Keenan K.P., Ballam G.C., Soper K.A., Laroque P., Colemen J.B., Dixit R. Diet, caloric restriction, and the rodent bioassay. Toxicol. Sci. 2009, 52(2Suppl):24-34.
114. King-Herbert A., Thayer K. NTP Workshop: animal models for the NTP rodent cancer bioassay: stocks and strains should we switch?. Toxicol. Pathol. 2006, 34:802-805.
115. King-Herbert A.P., Sills R.C., Bucher J.R. Commentary: update on animal models for NTP studies. Toxicol. Pathol. 2010, 38:180-181.
116. Krewski D., Brown C., Murdoch D. Determining " safe" levels of exposure: safety factors or mathematical models?. Fund. Appl. Toxicol. 1984, 4:S383-S394.
117. Krishnan K., Andersen M.F. Physiologically-based pharmacokinetic and toxicokinetic models. Principles and Methods of Toxicology 2007, 179-292. CRC Press, Taylor & Francis, NY, 2270 pp. fifth ed. A.W. Hayes (Ed.).
118. Lin K.K. Progress report on the guidance for industry for statistical aspects of the design, analysis, and interpretation of chronic rodent carcinogenicity studies of pharmaceuticals. J. Biopharm. Stat. 2000, 10:481-501.
119. MacDonald J., French J.E., Gerson R.J., Goodman J., Inoue T., Jacobs A., Kasper P., Keller D., Lavin A., Long G., McCullough B., Sistare F.D., Storer R., van der Laan J.W. The utility of genetically modified mouse assays for identifying human carcinogens. The Alternatives to Carcinogenicity Testing Committee ILSI-HESI. Toxicol. Sci. 2004, 77:188-194.
120. Magnuson, B., Williams, G.M., 2008. Carcinogenicity of apartame in rats not proven. Environ. Health Perspect. 116, 239-240. Available from: (accessed November, 2009). http://www.ncbi.nlm.nih.gov/pmc/.
121. Magnuson B.A., Burdock G.A., Doull J., Kroes R.M., Marsh G.M., Pariza M.W., Spencer P.S., Waddell W.J., Walker R., Williams G.M. Aspartame: a safety evaluation based on current use levels, regulations, and toxicological and epidemiological studies. Crit. Rev. Toxicol. 2007, 37:629-727.
122. Maltoni C., Soffritti M., Belpoggi F. The scientific and methodological bases of experimental studies for detecting and quantifying carcinogenic risks. Eur. J. Oncol. 1999, 3:5-10.
123. McConnell E.E. Comparative responses in carcinogenesis bioassays as a function of age at first exposure. Similarities & Differences Between Children & Adults 1992, 66-78. ILSI Press, Washington, DC, 285 pp. P.S. Guzelian, C.J. Henry, S.S. Olin (Eds.).
124. McConnell E.E., Solleveld H.A., Swenberg J.A., Boorman G.A. Guidelines for combining neoplasms for evaluation of rodent carcinogenesis studies. J. Nat. Cancer Inst. 1986, 76:283-289.
125. Melnick R.L., Thayer K.A., Bucher J.R. Conflicting views arising from the design and evaluation of rodent carcinogenicity studies. Environ. Health Persp. 2008, 116:130-135.
126. Handbook of Carcinogen Testing 1994, William Andrew Publ., NY, 904 pp. second ed.
127. Mohr, U., 1992-1997. International Classification of Rodent Tumours, Part I: The Rat. 10 Volumes, IARC Scientific Publ. Series 122.
128. Mohr U. International Classification of Rodent Tumours: The Mouse 2001, Springer Publ., 474 pp.
129. Molon-Noblot S., Laroque P., Coleman J.B., Hoe C.M., Keenan K.P. The effects of ad libitum overfeeding and moderate and marked dietary restriction on age-related spontaneous pituitary gland pathology in Sprague-Dawley rats. Toxicol. Pathol. 2003, 31:310-320.
130. Monro A. Are lifespan rodent carcinogenicity studies defensible for pharmaceutical agents? Exp. Toxicol. Pathol. 1996, 48:155-166.
131. Newberne P.M., Sotnikov A.V. Diet: the neglected variable in chemical safety evaluations. Toxicol. Pathol. 1996, 24:746-756.
132. Nold J.B., Keenan K.P., Nyska A., Cartwright M.E. Society of toxicology pathology position paper: diet as a variable in rodent toxicology and carcinogenicity studies. Toxicol. Pathol. 2001, 29:585-586.
133. NRC (National Research Council), 1993. Use of the maximum tolerated dose in animal bioassays for carcinogenicity. In: Goldstein, B. et al. (Eds.), Issues in Risk Assessment, pp. 15-83 (Cited in Haseman and Lockhart (1994)).
134. NRC, 1994. Science and Judgement in Risk Assessment. National Academy Press, Washington, DC, 651 pp. Available from: (accessed November, 2009). http://www.nap.edu/openbook.php.
135. NRC, 1996. Guide to the Care and Use of Laboratory Animals. Institute of Laboratory Animal Resources (ILAR). National Academy Press, Washington, 125 pp. Available from: (accessed November, 2009). http://www.nap.edu/openbook.php.
136. NTP (National Toxicology Program), 2006. Specifications for the conduct of studies to evaluate the toxic and carcinogenic potential of chemical, biological and physical agents in laboratory animals for the National Toxicology Program (NTP). October 2006. Available from: (accessed October, 2009). http://ntp.niehs.nih.gov/.
137. OECD (Organization for Economic Cooperation and Development), 1981. OECD Guideline for Testing of Chemicals. Guideline 451: Carcinogenicity Studies, 15 pp. Adopted May 12, 1991.
138. OECD, 1998. OECD Series on Application of Principles of Good Laboratory Practice and Compliance Monitoring. OECD Principles on Good Laboratory Practice (as revised in 1997). Document: ENV/MC/CHEM (98)17. Available from: (accessed October, 2009). http://www.olis.oecd.org/.
139. OECD, 2006. Draft Revised Version of the DRP No.31 on Cell Transformation Assays for Detection of Chemical Carcinogens. Available from: (accessed October, 2009). http://www.oecd.org/.
140. OECD, 2009a. OECD Guideline for the Testing of Chemicals. Test Guideline 451: Carcinogenicity Studies. 15 pp. Available from: (accessed October, 2009). http://lysander.sourceoecd.org.
141. OECD, 2009b. Draft Guidance Document on the Design and Conduct of Chronic Toxicity and Carcinogenicity Studies, Series on Testing and Assessment No. 116. Available from: (accessed October, 2009). http://www.oecd.org.
142. Õkva K., Tamoševičiūte E., Čižiūte A., Pokk P., Rukšenas O., Nevalainen T. Refinements for intragastric gavage in rats. Scand. J. Lab. Animal Sci. 2006, 33:243-252.
143. Pastoor T., Stevens J. Historical perspective of the cancer bioassay. Scand. J. Environ. Health. 2005, 31(Suppl. 1):129-140.
144. Peto, R., Pike, M.C., Day, N.E., Gray, R.G., Lee, P.N., Parish, S., Peto, J., Richards, S., Wahrendorf, J., 1980. " Guidelines for simple, sensitive, significance tests for carcinogenic effects in long-term animal experiments" In: Long-term and Short-term Screening Assays for Carcinogens: A Critical Appraisal. World Health Organization. Cited in Lin (2000) referenced herein.
145. Portier C., Hoel D. Optimal design of the chronic animal bioassay. J. Toxicol. Environ. Health 1983, 12:1-19.
146. Portier C.J., Hoel D.G. Design of animal carcinogenicity studies for goodness-of-fit of multistage models. Fund. Appl. Toxicol. 1984, 4:949-959. Cited in Rhomberg et al. (2007) referenced herein.
147. Pritchard J.B., French J.E., Davis B.J., Haseman J.K. The role of transgenic mouse models in carcinogen identification. Environ. Health Persp. 2003, 111:444-454.
148. Rao G.N. Diet for Fischer-344 rats in long-term studies. Environ. Health Perspect. 1994, 102:314-315.
149. Rao G.N., Morris R.W., Seely J.C. Beneficial effects of NTP-2000 diet on growth, survival, and kidney and heart diseases of Fischer 344 rats in chronic studies. Toxicol. Sci. 2001, 63:245-255.
150. Renwick, A.G. Toxicokinetics, p. 214. In: Hayes, A.W. (Ed.), Principles and Methods of Toxicology, fifth ed. CRC Press, Taylor & Francis, NY, p. 2270.
151. Reuter J., Hobbelen H. The effect of continuous light exposure on the retina in albino and pigmented rats. Physiol. Behav. 1977, 18:939-944.
152. Rhomberg L.R., Baetcke K., Blancato J., Bus J., Cohen S., Conolly R., Dixit R., Doe J., Ekelman K., Fenner-Crisp P., Harvey P., Hattis D., Jacobs A., Jacobson-Kram D., Lewandowski T., Liteplo R., Pelkonen O., Rice J., Somers D., Turturro A., West W., Olin S. Issues in the design and interpretation of chronic toxicity and carcinogenicity studies in rodents: Approaches to dose selection. Crit. Rev. Toxicol. 2007, 37:729-837.
153. Rice J.M. Problems and perspectives in perinatal carcinogenesis: a summary of the conference. Nat. Cancer Inst. Monogr. 1979, 51:271-278.
154. Riley V. Psychoneuroendocrine influences on immunocompetence and neoplasia. Science 1981, 212:1100-1109.
155. RITA (Registry of Industrial Toxicology Animal data), 2009. Continuous advancement of rodent tumor data acquisition and interpretation. Available from: (accessed December, 2009). http://reni.item.fraunhofer.de/reni/public/rita/.
156. Robens, J.F., Calabrese, E.J., Piegorsch, W.W., Schueler, R.L., Hayes, A.W., 1994. Principles of testing for carcinogenicity. In: Hayes, A.W. (Ed.), Principles and Methods of Toxicology, third ed. Raven Press, NY, pp. 697-728 (Chapter 19).
157. Robinson D.E., MacDonald J.S. Background and framework for ILSI's collaborative evaluation program on alternative models for carcinogenicity assessment. International Life Sciences Institute. Toxicol. Pathol. 2001, 29:13-19. Available from: (accessed November, 2009).
158. Rozman K.K. Letter to the editor. Toxicol. Sci. 2003, 75:224-225.
159. Rozman K.K., Kerecsen L., Viluksela M.K., Österle D., Deml E., Viluksela M., Stahl B.U., Greim H., Doull J. A toxicologist's view of cancer risk assessment. Drug Metab. Rev. 1996, 28:29-52.
160. Rushton, B., 1994. Oncogenicity/carcinogenicity. In: Cartwright, A.C., Matthews, B.R. (Eds.), International Pharmaceutical Product Registration. Aspects of Quality, Safety and Efficacy. Ellis Horwood Ltd, NY, pp. 553-568 (Chapter 15).
161. Seilkop S.K. The effect of body weight on tumor incidence and carcinogenicity testing in B6C3F1 mice and F344 rats. Fund. Appl. Toxicol. 1995, 24:247-259.
162. Soffritti M. Carcinogenicity of aspartame: soffritti responds. Environ. Health Perspect. 2008, 116:A240-A241. Available from: (accessed November, 2009).
163. Soffritti, M., Belpoggi, F., 2005. Long-term carcinogenicity bioassay to evaluate the potential biological effects, in particular carcinogenic, of aspartame administered in feed to Sprague-Dawley rats (Protocol No.: BT 6008). Unpublished report of the European Foundation of Oncology and Environmental Sciences " B. Ramazzini" , December 2005, Bologna, Submitted to EFSA. In EFSA (2006) cited separately herein.
164. Soffritti M., Belpoggi F., Minardi F., Maltoni C. Mega-experiments to identify and assess diffuse carcinogenic risks. Ann. NY Acad. Sci. 1999, 895:34-55.
165. Soffritti M., Belpoggi F., Minardi F., Maltoni C. Ramazzini Foundation Cancer Program. History and major projects, life-span carcinogenicity bioassay design, chemicals studied, and results. Ann. NY Acad. Sci. 2002, 982:26-45.
166. Soffritti M., Belpoggi F., Esposti D.D., Lambertini L. Aspartame induces lymphomas and leukaemias in rats. Eur. J. Oncol. 2005, 10:107-116.
167. Soffritti M., Soffritti M., Belpoggi F., Tibaldi E., Esposti D.D., Lauriola M. First experimental demonstration of the multipotential carcinogenic effects of aspartame administered in the feed to Sprague-Dawley rats. Environ. Health Perspect. 2006, 114:379-385.
168. Soffritti M., Belpoggi F., Tibaldi E., Esposti D.D., Lauriola M. Life-span exposure to low doses of aspartame beginning during fetal life. Environ. Health Perspect. 2007, 115:1293-1297.
169. Soffritti M., Belpoggi F., Esposti D.D., Falcioni L., Bua L. Consequences of exposure to carcinogens beginning during developmental life. Basic Clin. Pharmacol. Toxicol. 2008, 102:118-124.
170. Solleveld H.A., McConnell E.E. The value and significance of life span and scheduled termination data in long-term toxicity and carcinogenesis studies. Toxicol. Pathol. 1985, 13:128-134.
171. Solleveld H.A., Haseman J.K., McConnell E.E. Natural history of body weight gain, survival, and neoplasia in the F344 rat. J. Natl. Cancer Inst. 1984, 72:929-940.
172. Sontag, J.M., Page, N.P., Safiotti, U., 1976. Guidelines for carcinogen bioassay in small rodents. DHSS Publication (NIH) 76-801. National Cancer Institute, Bethesda, MD.
173. Spalding J.W., French J.E., Tice R.R., Furedi-Machacek M., Haseman J.K., Tennant R.W. Development of a transgenic mouse model for carcinogenesis bioassays: evaluation of chemically induced skin turmor in Tg.AC mice. Toxicol. Sci. 1999, 49:241-254.
174. Spalding J.W., French J.E., Stasiewicz S., Furedi-Machacek M., Conner F., Tice R.R., Tennant R.W. Responses of transgenic mouse lines p53(=/-) and Tg.AC to agents tested in conventional carcinogenicity bioassays. Toxicol. Sci. 2000, 53:213-223.
175. STP (Society of Toxicologic Pathologists), 1997. Documentation of pathology peer review: position of the Society of Toxicologic Pathologists. Toxicol. Pathol. 6, 655.
176. STP (Society of Toxicologic Pathologists), 2009. Standardized System of Nomenclature and Diagnostic Criteria (SSNDC) Guides: Series of 31 online publications for guidance on evaluation of animal tumors. Available from: (accessed October, 2009). http://www.toxpath.org/ssndc.asp.
177. Suckhow M.A., Weisbroth S.H., Franklin C.L. The Laboratory Rat 2006, Academic Press, NY, 912 pp. second ed.
178. Sumner D.D., Stevens J.T. Pharmacokinetic factors influencing risk assessment: saturation of biochemical processes and cofactor depletion. Environ. Health Perspect. 1994, 102(Suppl1):13-22.
179. Swenburg J.A. Bioassay design and MTD setting: old methods and new approaches. Reg. Toxicol. Pharmacol. 1995, 21:44-51.
180. Tannenbaum A. The initiation and growth of tumors. Introduction. I. Effects of underfeeding. Am. J. Cancer 1940, 38:335-350.
181. Tannenbaum A., Vesselinovitch S.D., Maltoni C., Mitchell D.S. Multipotential carcinogenicity of urethan in the Sprague-Dawley rat. Cancer Res. 1962, 22:1362-1371. Available from: (accessed November, 2009).
182. Tennant R.W., French J.E., Spalding J.W. Identifying chemical carcinogens and assessing potential risk in short-term bioassays using transgenic mouse models. Environ. Health Perspect. 1993, 103:942-950.
183. Tennant R.W., Spalding J., French J.E. Evaluation of transgenic mouse bioassays for identifying carcinogens and non carcinogens. Mut. Res. 1996, 365:119-127.
184. Thompson K.L., Rosenzweig B.A., Sistare F.D. An evaluation of the hemizygous transgenic Tg. AC mouse for carcinogenicity testing of pharmaceutical. II. A genotypic marker that predicts tumorigenic responsiveness. Toxicol. Pathol. 1998, 26:548-555.
185. US Animal Welfare Act, 1966. Animal Welfare Act 7 USC, 2131-2159, Animal Welfare Regulations and Final Rules Animal Welfare. Available from: (accessed December, 2009). http://awic.nal.usda.gov/.
186. Van der Laan J.W., Lima B.S., Snodin D. Alternative models in carcinogenicity testing: a European perspective. Toxicol. Pathol. 2002, 30:157-159. Available from: (accessed November, 2009).
187. Vesselinovitch S.D., Mihailovich N. Significance of newborn age and dose of urethane in leukemogenesis. Cancer Res. 1966, 26:1633-1637.
188. Vesselinovitch S.D., Mihailovich N. The neonatal and infant age period as biologic factors which modify multicarcinogenesis by urethane. Cancer Res. 1967, 27:1422-1429.
189. Visscher M.B., Ball Z.B., Barnes R.H., Siversten I. The influence of caloric restriction upon the incidence of spontaneous mammary carcinoma in mice. Surgery 1942, 11:48-55.
190. Waddell W.J. Thresholds of carcinogenicity of flavors. Toxicol. Sci. 2002, 68:275-279.
191. Waddell W.J. Thresholds of carcinogenicity in the ED01 study. Toxicol. Sci. 2003, 72:158-163.
192. Waddell W.J. Thresholds in chemical carcinogenesis: what are animal experiments telling us?. Toxicol. Pathol. 2003, 31:260-262.
193. Waddell W.J. Threshold for carcinogenicity of N-nitrosodiethylamine for esophageal tumors in rats. Food Chem. Toxicol. 2003, 41:739-741.
194. Waddell W.J. Comparison of human exposures to selected chemicals with thresholds from NTP carcinogenicity studies in rodents. Human Exp. Toxicol. 2003, 22:501-506.
195. Waddell W.J. Dose-response curves in chemical carcinogenesis. Nonlinearity in Biology, Toxicology, and Medicine 2004, 2:11-20.
196. Waddell W.J. Analysis of thresholds for carcinogenicity. Toxicol. Lett. 2004, 149:415-419.
197. Waddell W.J. Comparisons of thresholds for carcinogenicity on linear and logarithmic dosage scales. Human Exp. Toxicol. 2005, 24:325-332.
198. Waddell W.J. Critique of dose response in carcinogenesis. Human Exp. Toxicol. 2006, 25:413-436.
199. Waddell W.J. Thermodynamic basis for expressing dose logarithmically. Toxicol. Appl. Pharmacol. 2008, 228:156-157.
200. Waddell W.J. History of dose response. J. Toxicol. Sci. 2010, 35:1-8.
201. Ward J.M. The two-year rodent carcinogenesis bioassay - Will it survive?. J. Toxicol. Pathol. 2007, 20:13-19.
202. Weaver J.L., Contrera J.F., Rosenzweig B.A., Thompson K.L., Faustino P.J., Strong J.M., Ellison C.D., Anderson L.W., Prasanna H.R., Long-Bradley P.E., Lin K.K., Zhang J., Sistare F.D. An evaluation of the hemizigous transgenenic Tg. AC mouse for carcinogenicity testing of pharmaceuticals. I. Evidence for a confounding nonresponder phenotype. Toxicol. Pathol. 1998, 26:532-540.
203. Weisburger E.K. History of the bioassay program of the National Cancer Institute. Prog. Exp. Tumor Res. 1983, 26:187-201.
204. Weisburger J.H., Williams G.M. Carcinogen testing: current problems and new approaches. Science 1981, 214:401-407.
205. Weisburger J.H., Klein M., Weisburger E.K., Glass R.M., Woodward G., Cronin M.T.I. A comparison of the effect of the carcinogen N-hydroxy-N-fluorenylacetamide in infant and weanling rats. J. Nat. Cancer Inst. 1970, 45:29-35.
206. Wells M.Y., Spencer Williams E. The transgenic mouse assay as an alternative test method for regulatory carcinogenicity studies-implications for REACH. Reg. Toxicol. Pharmacol. 2009, 53:150-155.
207. White, W.J., Lee, C.S., 1998. The development and maintenance of the Crl:CD®(SD)IGS BR rat breeding system. Charles River Laboratories: CD(SD) IGS 1998; 8-14. Available from: http://paicriver.com.
208. Williams G.M. Applicaation of mode-of-action considerations in human cancer risk assessment. Toxicol. Lett. 2008, 180:75-80.
209. Williams, G.M., Iatropoulos, J.M., Enzmann, H.G., 2008. Principles of testing for carcinogenic activity, pp. 1265-1316. In: Hayes, A.W. (Ed.), Principles and Methods of Toxicology, fifth ed. CRC Press, Taylor & Francis, NY, 2270 pp.